drugset
drugset / Trial / NCT01820624

Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01820624 ↗

Phase 1 Completed 12 enrolled Paolo Caimi, MD National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of tretinoin when given together with lithium carbonate in treating patients with relapsed or refractory acute myeloid leukemia. Lithium carbonate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Tretinoin may help \[type of cancer\] cells become more like normal cells, and to grow and spread more slowly. Giving lithium carbonate together with tretinoin may kill more cancer cells

Timeline

Start
2013-04-30
Primary completion
2015-10-09
Completion
2015-11-13

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Lithium Carbonate Unknown 300 mg Oral
Subject Tretinoin Small molecule 22.5 mg/m2 Oral
Subject Tretinoin Small molecule 45 mg/m2 Oral

Indications

acute erythroid leukemia acute megakaryoblastic leukemia in adult acute myeloblastic leukemia with maturation acute myeloblastic leukemia without maturation acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myelomonocytic leukemia M4 adult acute monocytic leukemia